Karyopharm Therapeutics I... (KPTI)
7.24
-0.71 (-8.93%)
At close: Mar 03, 2025, 3:59 PM
Karyopharm Therapeutics Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Cash & Equivalents | 62.48M | 52.23M | 135.19M | 190.46M | 85.92M | 128.86M | 118.02M | 69M | 49.66M | 58.36M | 150.61M | 155.97M | 391K | 6.51M |
| Short-Term Investments | 46.24M | 139.21M | 142.78M | 38.16M | 163.32M | 133.1M | 210.18M | 77.47M | 79.89M | 117.28M | 55.12M | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | 633K | 637K | 24.21M | 2.02M | 2M | 29.4M | 45.43M | 33.88M | 8.66M | n/a | n/a | n/a |
| Other Long-Term Assets | 1.64M | 1.64M | 23.41M | 44.93M | -2.92M | 16.24M | 716K | 290K | 479K | 482K | 1.17M | 30K | 30K | 30K |
| Receivables | 30.77M | 26.96M | 47.09M | 22.5M | 12.88M | 7.86M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Inventory | 4.74M | 3.04M | 4.22M | 4.11M | 2.64M | 346K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Assets | 12.28M | 12.47M | 20.89M | 20.39M | 11.77M | 8.41M | 12.83M | 3.71M | 4.17M | 3.93M | 4.05M | 3.96M | 563K | 354K |
| Total Current Assets | 156.49M | 233.92M | 326.75M | 258.1M | 289.54M | 273.67M | 334.61M | 148.42M | 131.64M | 177.6M | 207.75M | 157.96M | 954K | 6.87M |
| Property-Plant & Equipment | 6.28M | 4.88M | 7.38M | 1.64M | 2.22M | 3.05M | 3.86M | 2.19M | 2.84M | 3.48M | 2.75M | 240K | 327K | 328K |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 7.93M | 6.52M | 31.42M | 47.21M | 23.51M | 21.3M | 6.58M | 31.87M | 48.75M | 37.84M | 12.59M | 270K | 357K | 358K |
| Total Assets | 164.42M | 240.44M | 358.17M | 305.31M | 313.05M | 294.96M | 341.19M | 180.29M | 180.38M | 215.44M | 220.34M | 158.23M | 1.31M | 7.22M |
| Account Payables | 5.11M | 3.12M | 2.77M | 1.6M | 4.45M | 985K | 4.33M | 5.67M | 4.75M | 3.81M | 6.29M | 1.74M | 1.08M | 1.14M |
| Deferred Revenue | n/a | n/a | n/a | 69.12M | 297K | 2.34M | 9.36M | 21.92M | 280K | 206K | n/a | 79K | 66K | 200K |
| Short-Term Debt | 876K | 3.31M | 5.74M | 4.63M | 3.83M | 3.29M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Current Liabilities | 86.28M | 63.05M | 57.39M | 67.48M | 51.62M | 39.73M | 33.21M | 21.88M | 11.72M | 11.32M | 6.01M | 1.47M | 788K | 775K |
| Total Current Liabilities | 92.26M | 69.48M | 65.91M | 73.72M | 297K | 46.35M | 46.9M | 49.47M | 16.48M | 15.13M | 12.3M | 2.91M | 1.93M | 2.12M |
| Long-Term Debt | 99.48M | 173.71M | 176.2M | 178.26M | 129.21M | 123.06M | 102.66M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Liabilities | 158.69M | 133.46M | 132.72M | 133M | 73.09M | n/a | 3.92M | 1.36M | 1.67M | n/a | 1.24M | -384K | 27.26M | 17.76M |
| Total Long-Term Liabilities | 258.17M | 307.17M | 374.83M | 384.98M | 262.21M | 245.19M | 111.12M | 1.36M | 1.67M | 1.95M | 1.24M | 384K | 27.26M | 17.76M |
| Total Liabilities | 350.44M | 376.64M | 374.83M | 384.98M | 262.5M | 245.19M | 158.02M | 50.83M | 18.14M | 17.08M | 13.54M | 3.29M | 29.19M | 19.88M |
| Total Debt | 99.92M | 177.02M | 172.98M | 169.29M | 117.93M | 109.86M | 102.66M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Common Stock | 13K | 12K | 12K | 8K | 7K | 7K | 6K | 5K | 4K | 4K | 3K | 3K | n/a | n/a |
| Retained Earnings | -1.56B | -1.49B | -1.34B | -1.18B | -1.07B | -873.34M | -673.75M | -495.34M | -366.1M | -256.53M | -138.35M | -62.57M | -28.62M | -12.73M |
| Comprehensive Income | -356K | -161K | -638K | 191K | 518K | -37K | -244K | -217K | -274K | -282K | -29K | -350K | -206K | -84K |
| Shareholders Equity | -186.02M | -136.21M | -16.66M | -79.67M | 50.55M | 49.77M | 183.17M | 129.46M | 162.24M | 198.37M | 206.79M | 154.93M | -27.88M | -12.65M |
| Total Investments | 46.24M | 139.21M | 142.78M | 38.16M | 187.54M | 135.11M | 212.18M | 106.87M | 125.32M | 151.15M | 63.77M | n/a | n/a | n/a |